Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis

International Seminars in Surgical Oncology

Volumn 2, Issue , 2005, Pages

  Srkalovic, Gordan ^a   Cameron, Marte G ^b   Deitcher, Steven R ^c   Kattke Marchant, Kandice ^d   Hussein, Mohamad A ^d  

^a Department of Medical Oncology and Hematology   (United States)

^b Avdeling Sandnessjøen ^*  (Norway)

^c Nuvelo Inc   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; M PROTEIN; MELPHALAN; PREDNISONE; RITUXIMAB; STEROID; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; AMYLOIDOSIS; ANAMNESIS; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; HYPERCOAGULABILITY; INCIDENCE; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; VENOUS THROMBOEMBOLISM;

EID: 27344457882     PISSN: 14777800     EISSN: 14777800     Source Type: Journal    
DOI: 10.1186/1477-7800-2-17     Document Type: Article

References (29)

1. Gertz MA, Kyle RA: Primary systemic amyloidosis - a diagnostic primer. Mayo Clinic 1989, Proc 64:1505.
2. Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Sem Hematol 1995, 32:45.
3. Glaspy JA: Hemostatic abnormalities in multiple myeloma and related disorders. Hem/Onc Clin North Amer 1992, 6(6): 1301-1315.
4. Greipp PR, Kyle RA, Bowie EJ: Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981, 11:443-450.
5. Catovsky D, Ikoku NB, Pitney WR, Galton DAG: Thromboembolic Complications in Myelomatosis. Brit Med J 1970, 3:438-439.
6. Tinaztepe K, Buyan N, Tinaztepe B, Akkok N: The association of nephrotic syndrome and renal vein thrombosis: a clinicopathological analysis of 8 pediatric patients. Turk J Ped 1989, 31(1):1-18.
7. Kim V, Spandorfer J: Epidemiology of venous thromboembolic disease. Emerg Med Clin N Amer 2001, 19(4):839-59.
8. Cameron JS: Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephr Necker Hosp 1984, 13:75-114.
9. Dubrey S, Pollak A, Skinner M, Falk RH: Atrial thrombi occuring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995, 74:541-544.
10. Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G: Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. amyloid 1999, 6(4):273-277.
11. Hirsch J, Lee A: How we diagnose and treat deep vein thrombosis. Blood 2002, 99:3102-3110.
12. Srkalovic G, Camerom MG, Rybicki L, Deitcher SR, Kottke-Marchant K, Hussein MA: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004, 101:558.
13. Baier J, Neumann H, Grossmann R, Ricken D: Primary amyloidosis and thrombophlebitis as complications of Bence-Jones plasmacytoma (lambda type). Medizinishe Klinik 1991, 86(1):53-57.
14. Gillum RF: Pulmonary embolism and thrombophlebitis in the United States, 1970-4 985. Am Heart J 1987, 114:1262-1264.
15. Gjores JE: The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chirurgica Scandinavica 1987, 111(suppl 206):16-24.
16. Nicolaides AN, Irving D: Clinical factors and the risk of deep venous thrombosis. In Thromboembolism Etiology, Advances in Prevention and Management Edited by: Nicolaides AN. Baltimore: University Park press; 1975:193-204.
17. Anderson FA Jr, Wheeler HB, Goldberg RJ: A population-based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Int Med 1991, 151:933-938.
18. Anderson FA Jr, Wheeler HB: Venous thromboembolis. Risk Factors and Prophylaxis. Clin Chest Medic 1995, 16(2):235-251.
19. Kyle RA, Greipp PR, O'Fallon WM: Primary systemic amylodosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986, 1:220-224.
20. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV: Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003, 101:827-830.
21. Dipsenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA: Eligibility for hematopoetic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001, 19(14):3350-3356.
22. Ancain JB, Kisilevsky R: The heparin/heparan sulfate-binding site on aposerum amyloid A: implicationfor the therapeutic intervention in amyloidosis. Int J Exp Clin Invest 1999, 6:37-47.
23. Meek RL, Urieli-Shoval S, Benditt EP: Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implication for serum amyloid A function. Proc Natl Acad Sci USA 1994, 91:3186-3190.
24. Urieli-Shoval S, Linke RP, Matzner Y: Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease state. Curr Opin Hematol 2000, 7:64-69.
25. Falk RH, Comenzo RL, Skinner M: The systemic amyloidosis. NEJM 1997, 337:898-909.
26. Cohen AS: amyloidosis. Bull Rheum Dis 1991, 40(2):1-12.
27. Grateau G: The relation between Familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol 2000, 12:61-64.
28. Jensen LE, Whitehead AS: Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998, 334:489-503.
29. Kerr R: Interleukin 6 and hemostasis. Br J Haematol 2001, 115:3-12.